These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21515049)

  • 21. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
    Shen G; Wang M; Welch TR; Blagg BS
    J Org Chem; 2006 Sep; 71(20):7618-31. PubMed ID: 16995666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
    J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
    Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
    J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
    Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
    Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo Evaluation of 17-phenylpropylamine/phenoxyethylamine- 17-demethoxygeldanamycins as Potent Hsp90 Inhibitors.
    Li Z; Jia L; Xu H; Lu C; Shena Y
    Med Chem; 2015; 11(5):482-8. PubMed ID: 25537129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
    Franke J; Eichner S; Zeilinger C; Kirschning A
    Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H; Kim YJ; Hahn JS
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors--potential therapeutics in cancer and neurodegeneration.
    Kitson RR; Moody CJ
    Chem Commun (Camb); 2013 Oct; 49(76):8441-3. PubMed ID: 23770604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.
    Zhang MQ; Gaisser S; Nur-E-Alam M; Sheehan LS; Vousden WA; Gaitatzis N; Peck G; Coates NJ; Moss SJ; Radzom M; Foster TA; Sheridan RM; Gregory MA; Roe SM; Prodromou C; Pearl L; Boyd SM; Wilkinson B; Martin CJ
    J Med Chem; 2008 Sep; 51(18):5494-7. PubMed ID: 18800759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New, non-quinone fluorogeldanamycin derivatives strongly inhibit Hsp90.
    Hermane J; Bułyszko I; Eichner S; Sasse F; Collisi W; Poso A; Schax E; Walter JG; Scheper T; Kock K; Herrmann C; Aliuos P; Reuter G; Zeilinger C; Kirschning A
    Chembiochem; 2015 Jan; 16(2):302-11. PubMed ID: 25572106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
    Jayanthan A; Fowler J; Hawkins L; Lamers F; Teja B; Incoronato A; Anderson R; Narendran A
    J Exp Ther Oncol; 2008; 7(3):183-93. PubMed ID: 19066127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
    Solár P; Horváth V; Kleban J; Koval' J; Solárová Z; Kozubík A; Fedorocko P
    Neoplasma; 2007; 54(2):127-30. PubMed ID: 17319785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors.
    Jadhav VD; Duerfeldt AS; Blagg BS
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6845-50. PubMed ID: 19896848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
    McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ
    Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational design and synthesis of ansa-adenosines as potential antitumor agents.
    Muranaka K; Ichikawa S; Matsuda A
    Nucleic Acids Symp Ser (Oxf); 2009; (53):5-6. PubMed ID: 19749232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.